Evaluation of Salivary ELISA for Hormone Monitoring in IVF Patients (SALIVA_MINT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: LAURA CARACENA
- Phone Number: 034963050900
- Email: Laura.Caracena@ivirma.com
Study Contact Backup
- Name: ANA SAEZ
- Phone Number: 034963050900
- Email: Ana.Saez@ivirma.com
Study Locations
-
-
-
Valencia, Spain, 46003
- IVI Valencia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing IVF/ICSI treatment
- Patients planned to embryo transfer (ET) undergoing hormonal replacement therapy
- Aged from18-45 years old.
- BMI 19-30 kg/m2
- Signed written informed consent
Exclusion Criteria:
• Patients suffering for any systemic disease or endocrine disorder will be excluded foe the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients undergoing ovarian stimulation for IVF/ICSI
90 patients undergoing ovarian stimulation for IVF/ICSI; Low, average and high responders will be included in equal proportions, in order to cover the widest range of hormonal values (30 blood and saliva samples per ovarian stimulation point will be taken for determination of progesterone and oestradiol).
|
Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
|
|
Experimental: Patients for embryo transfer (ET) undergoing hormonal replacement therapy
30 patients for embryo transfer (ET) undergoing hormonal replacement therapy.
These patients will only have a progesterone determination in their blood and saliva samples on the day of ET.
|
Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the correlation between salivary ELISA assays and serum determination of progesterone and oestradiol concentrations IVF patients.
Time Frame: 12 months
|
between salivary ELISA assays and serum determination of progesterone and oestradiol concentrations
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diurnal variability of salivary progesterone and oestradiol levels
Time Frame: 12 months
|
Measurement of progesterone and oestradiol levels
|
12 months
|
|
Patient User Experience with saliva collection
Time Frame: 12 months
|
Registry of patient experience with saliva collection as users using a specific questionary.
(Yes/No question)
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2107-VLC-071-EB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.